Plasma β-amyloid and duration of Alzheimer's disease in adults with Down syndrome

International Journal of Geriatric Psychiatry

Volumn 25, Issue 2, 2010, Pages 202-207

  Prasher, V P ^a   Sajith, S G ^b   Mehta, P ^c   Zigman, W B ^c   Schupf, N ^c,d  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b Ashley House   (United Kingdom)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

amyloid; Alzheimer's disease; Down syndrome

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E;

ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; GENOTYPE; HUMAN; MALE;

ADULT; AGED; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; COHORT STUDIES; DEMENTIA; DOWN SYNDROME; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 75749115175     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2321     Document Type: Article

References (41)

1. Aylward EH, Burt DB, Thorpe LU, Lai F, Dalton A. 1997. Diagnosis of dementia in individuals with intellectual disability. J Intellect Disabil Res 41: 152-164.
2. Bassuk SS, Wypij D, Berkman LF. 2000. Cognitive impairment and mortality in the community-dwelling elderly. Am J Epidemiol 151: 676-688.
3. Burt DB, Aylward EH. 2000. Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the establishment of criteria for the diagnosis of dementia in individuals with intellectual disability. J Intellect Disabil Res 44: 175-180.
4. Coppus A, Evenhuis H, Verberne GJ, et al. 2006. Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res 50: 768-777.
5. Corder EH, Saunders AM, Strittmatter WJ, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
6. Cosentino S, Scarmeas N, Helzner E, et al. 2008. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 70: 1842-1849.
7. Craft S, Teri L, Edland SD, et al. 1998. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 51: 149-153.
8. Englund H, Annerén G, Gustafsson J, et al. 2007. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. Dement Geriatr Cogn Disord 24: 369-374.
9. Ertekin-Taner N, Younkin LH, Yager DM, et al. 2008. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70: 506-606.
10. Fagan AM, Roe CM, Xiong C, et al. 2007. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349.
11. Fried LP, Kronmal RA, Newman AB, et al. 1998. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 279: 585-592.
12. Frisoni GB, Govoni S, Geroldi C, et al. 1995. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 37: 596-604.
13. Graff-Radford NR, Crook JE, Lucas J, et al. 2007. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64: 354-362.
14. Hansson O, Buchhave P, Zetterberg H, et al. .2009. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 30: 165-173.
15. Kawarabayashi T, Younkin LH, Saido TC, et al. 2001. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381.
16. Koch W, Ehrenhaft A, Griesser K, et al. 2002. TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med 40: 1123-1131.
17. Kosaka T, Imagawa M, Seki K, et al. 1997. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 48: 741-745.
18. Liu IY, LaCroix AZ, White LR, Kittner SJ, Wolf PA. 1990. Cognitive impairment and mortality: a study of possible confounders. Am J Epidemiol 132: 136-143.
19. Mann DMA. 1991. The topographic distribution of brain atrophy in Alzheimer's disease. Acta Neuropathol 83: 81-86.
20. Mayeux R, Stern Y, Ottman R, et al. 1993. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol 34: 752-754.
21. Mayeux R, Tang MX, Jacobs DM, et al. 1999. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46: 412-416.
22. Mayeux R, Honig LS, Tang MX, et al. 2003. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61: 1185-1190.
23. Mehta PD, Dalton AJ, Mehta SP, et al. 1998. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241: 13-16.
24. Mehta PD, Mehta SP, Fedor B, et al. 2003. Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome. Neurosci Lett 342: 155-158.
25. Mehta PD, Capone G, Jewell A, Freedland RL. 2007. Increased amyloid beta protein levels in children and adolescents with Down syndrome. J Neurol Sci 254: 22-27.
26. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. 2005. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 13: 914-917.
27. Prasher VP. 2005. Down Syndrome and Alzheimer's Disease: Biological Correlates. Radcliffe Press: London.
28. Prasher VP, Sajith SG, Rees SD. 2008. Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome. Int J Geriatr Psychiatry 23: 1134-1140.
29. Ringman JM, Younkin SG, Pratico D, et al. 2008. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71: 85-92.
30. Rumble B, Retallack R, Hilbich C, et al. 1989. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320: 1446-1452.
31. Schupf N, Kapell D, Nightingale B, et al. 1996. Onset of dementia is associated with apolipoprotein E epsilon4 in Down's syndrome. Ann Neurol 40: 799-801.
32. Schupf N, Patel B, Silverman W, et al. 2001. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301: 199-203.
33. Schupf N, Patel B, Silverman W, et al. 2002. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 180: 405-410.
34. Schupf N, Patel B, Pang D, et al. 2007. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol 64: 1007-1013.
35. Sundelof J, Giedraitis V, Irizarry MC, et al. 2008. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65: 256-263.
36. Teller JK, Russo C, DeBusk LM, et al. 1996. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2: 31-32.
37. Tokuda T, Fukushima T, Ikeda S, et al. 1997. Plasma levels of amyloid beta proteins Abeta 1-40 and Abeta1-42(43) are elevated in Down's syndrome. Ann Neurol 41: 271-273.
38. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. 2006. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5: 655-660.
39. WHO 1992. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. World Health Organization: Geneva.
40. WHO 1993. The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research. World Health Organization: Geneva.
41. WHO 1994. ICD-10 Symptom Checklist for Mental Disorders. Version 1.1. World Health Organization: Geneva.